Hanmi Pharm. Co., Ltd.

Korea Institute of Science and Technology

Hanmi Science Co., Ltd.

Catholic University Industry Academic Cooperation Foundation

Jae Yul Choi

Tae Woo Kim

Young Gil Ahn

In Hwan Bae

Kwee Hyun Suh

Seok Jong Kang

Ji Sook Kim

Young Jin Ham

Ji Young Song

Seo Hee Kim

Hwan Mook Kim

Dong-wook Kim

Hwan Geun Choi

Jae Chul Lee

Eun Young Kim

Ji Yeon Song

Tae Bo Sim

Jung Beom Son

Maeng Sup Kim

Seung Hyun Jung

Young Hee Jung

Dong-sik Park

Wha Il Choi

Kyu Hang Lee

Wha Ii Choi

Jung Soo Nam

Min Jeong Kim

Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.

Imidazopyridine derivative compounds and use of same

Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof in a therapeutically effective combination, and a method of treating AML using the composition.

Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia

Provided are: a pharmaceutical composition for treating myeloid leukemia (AML), and a method for treating acute myeloid leukemia using same, the pharmaceutical composition comprising a therapeutically effective combination of an Fms-like tyrosine kinase-3 (FLT3) inhibitor or pharmaceutically acceptable salt or solvate thereof, and a chemotherapeutic agent or pharmaceutically acceptable salt or solvate thereof.

Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.

Pyrimidine compound and pharmaceutical use thereof

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases

Growing community of inventors

Hwaseong-si, South Korea

Jae Yul Choi